Acoltremon
Molecular structure of acoltremon | |
3D representation of an acoltremon molecule | |
| Clinical data | |
|---|---|
| Trade names | Tryptyr |
| Other names | AVX-012, WS-12 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625071 |
| License data |
|
| Routes of administration | Eye drop |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H27NO2 |
| Molar mass | 289.419 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Acoltremon sold under the brand name Tryptyr, is a medication used for the treatment of dry eye syndrome. Acoltremon is a transient receptor potential melastatin 8 (TRPM8) thermoreceptor agonist. It is used as an eye drop.
The most common treatment-emergent adverse event experienced during the clinical studies was instillation site pain (burning or stinging) events.
Acoltremon was approved for medical use in the United States in May 2025. The US Food and Drug Administration considers it to be a first-in-class medication.
Category:
- Drugs not assigned an ATC code